nteracting Epidemics in Amazonian Brazil: Prior Dengue Infection Associated With Increased Coronavirus Disease 2019 (COVID-19) Risk in a Population-Based Cohort Stud

Autor(es):Mostrar menos -

Nicolete, Vanessa C. ^[1] ; Rodrigues, Priscila T. ^[1] ; Johansen, Igor C. ^[1] ; Corder, Rodrigo M. ^[1] ; Tonini, Juliana ^[1] ; Cardoso, Marly A. ^[2] ; de Jesus, Jaqueline G. ^{[3, 4]} ; Claro, Ingra M. ^{[3, 4]} ; Faria, Nuno R. ^{[5, 6, 3, 4]} ; Sabino, Ester C. ^{[3, 4]} ; Castro, Marcia C. ^[7] ; Ferreira, Marcelo U. ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Inst Biomed Sci, Dept Parasitol, Sao Paulo - Brazil

^[2] Univ Sao Paulo, Sch Publ Hlth, Dept Nutr, Sao Paulo - Brazil

^[3] Univ Sao Paulo, Med Sch, Inst Trop Med, Sao Paulo - Brazil

^[4] Univ Sao Paulo, Med Sch, Dept Infect & Parasit Dis, Sao Paulo - Brazil

^[5] Univ Oxford, Dept Zool, Oxford - England

^[6] Imperial Coll London, Dept Infect Dis Epidemiol, London - England

^[7] Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA - USA

• Tipo de documento: Artigo Científico
• Fonte: Clinical Infectious Diseases; v. 73, n. 11, p. 2045-2054, DEC 6 2021.
• Citações Web of Science: 0

Resumo

Background Immunity after dengue virus (DENV) infection has been suggested to cross-protect from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and mortality. Methods We tested whether serologically proven prior DENV infection diagnosed in September-October 2019, before the coronavirus disease 2019 (COVID-19) pandemic, reduced the risk of SARS-CoV-2 infection and clinically apparent COVID-19 over the next 13 months in a population-based cohort in Amazonian Brazil. Mixed-effects multiple logistic regression analysis was used to identify predictors of infection and disease, adjusting for potential individual and household-level confounders. Virus genomes from 14 local SARS-CoV-2 isolates were obtained using whole-genome sequencing. Results Anti-DENV immunoglobulin G (IgG) was found in 37.0% of 1285 cohort participants (95% confidence interval {[}CI]: 34.3% to 39.7%) in 2019, with 10.4 (95% CI: 6.7-15.5) seroconversion events per 100 person-years during the follow-up. In 2020, 35.2% of the participants (95% CI: 32.6% to 37.8%) had anti-SARS-CoV-2 IgG and 57.1% of the 448 SARS-CoV-2 seropositives (95% CI: 52.4% to 61.8%) reported clinical manifestations at the time of infection. Participants aged >60 years were twice more likely to have symptomatic COVID-19 than children under 5 years. Locally circulating SARS-CoV-2 isolates were assigned to the B.1.1.33 lineage. Contrary to the cross-protection hypothesis, prior DENV infection was associated with twice the risk of clinically apparent COVID-19 upon SARS-CoV-2 infection, with P values between .025 and .039 after adjustment for identified confounders. Conclusions Higher risk of clinically apparent COVID-19 among individuals with prior dengue has important public health implications for communities sequentially exposed to DENV and SARS-CoV-2 epidemics. (AU)

• Processo FAPESP: 16/18740-9 - Bases científicas para a eliminação da malária residual na Amazônia Brasileira
• Beneficiário: Marcelo Urbano Ferreira
• Modalidade de apoio: Auxílio à Pesquisa - Temático
• Processo FAPESP: 18/14389-0 - Centro Conjunto Brasil-Reino Unido para Descoberta, Diagnóstico, Genômica e Epidemiologia de Arbovírus (CADDE)
• Beneficiário: Ester Cerdeira Sabino
• Modalidade de apoio: Auxílio à Pesquisa - Temático
• Processo FAPESP: 20/04505-3 - Mapeando a disseminação de SARS-CoV-2: dimensão do surto, dinâmica de transmissão, desfechos clínicos da infecção e duração da respostas de anticorpos em uma pequena cidade amazônica
• Beneficiário: Marcelo Urbano Ferreira
• Modalidade de apoio: Auxílio à Pesquisa - Regular